Javascript must be enabled to continue!
Circulating and Exosomal microRNA-33 in Childhood Obesity
View through CrossRef
Background: MicroRNA-33 may control a wide range of different metabolic functions. Methods: This study aims to assess the miR-33a circulating profile in normal-weight (N = 20) and obese (O = 30) adolescents and to correlate its expression levels to their metabolic parameters. In a subset of subjects, we compared circulating miR-33a with exosomal miR-33a. Results: Metabolic parameters were altered in O, with initial hyperinsulinemia. Circulating miR-33a was significantly higher in O than in N (p = 0.0002). Significant correlations between miR-33a and auxological and metabolic indices (Insulin p = 0.01; Cholesterol p = 0.01; LDL p = 0.01; HbA1c p = 0.01) were found. Splitting our population (O + N) into two groups, according to the median value of mRNA expression miR-33a levels (0.701), irrespective of the presence or absence of obesity, we observed that those having a higher expression of miR-33a were more frequently obese (87.5% vs. 12.5%; p < 0.0001) and had significantly increased values of auxological and metabolic parameters. Exosomes extracted from plasma of N and O carried miR-33a, and its expression was lower in O (p = 0.026). No correlations with metabolic parameters were observed. Conclusion: While exosome miR-33a does not provide any advantage, circulating miR-33a can provide important indications in an initial phase of metabolic dysfunction, stratifying obese adolescents at higher cardiometabolic risk.
Title: Circulating and Exosomal microRNA-33 in Childhood Obesity
Description:
Background: MicroRNA-33 may control a wide range of different metabolic functions.
Methods: This study aims to assess the miR-33a circulating profile in normal-weight (N = 20) and obese (O = 30) adolescents and to correlate its expression levels to their metabolic parameters.
In a subset of subjects, we compared circulating miR-33a with exosomal miR-33a.
Results: Metabolic parameters were altered in O, with initial hyperinsulinemia.
Circulating miR-33a was significantly higher in O than in N (p = 0.
0002).
Significant correlations between miR-33a and auxological and metabolic indices (Insulin p = 0.
01; Cholesterol p = 0.
01; LDL p = 0.
01; HbA1c p = 0.
01) were found.
Splitting our population (O + N) into two groups, according to the median value of mRNA expression miR-33a levels (0.
701), irrespective of the presence or absence of obesity, we observed that those having a higher expression of miR-33a were more frequently obese (87.
5% vs.
12.
5%; p < 0.
0001) and had significantly increased values of auxological and metabolic parameters.
Exosomes extracted from plasma of N and O carried miR-33a, and its expression was lower in O (p = 0.
026).
No correlations with metabolic parameters were observed.
Conclusion: While exosome miR-33a does not provide any advantage, circulating miR-33a can provide important indications in an initial phase of metabolic dysfunction, stratifying obese adolescents at higher cardiometabolic risk.
Related Results
Serum expression of microRNA-21, microRNA-125a, microRNA-125b, microRNA-214 in coronary artery disease patients
Serum expression of microRNA-21, microRNA-125a, microRNA-125b, microRNA-214 in coronary artery disease patients
Background. Coronary artery disease (CAD) is determined by interaction of environmental factors with epigenetic and genetic factors. MicroRNA-21, microRNA-125a, microRNA-125b and m...
Variants of the vitamin D receptor gene and the expression of microRNA‑21, microRNA‑125a, microRNA‑125b and microRNA‑214 in coronary heart disease
Variants of the vitamin D receptor gene and the expression of microRNA‑21, microRNA‑125a, microRNA‑125b and microRNA‑214 in coronary heart disease
Background. The protective effects of vitamin D in relation to atherogenesis are realized by vitamin D receptors (VDR). Variants rs10735810, rs731236, rs1544410 and rs797532 of the...
MicroRNA-34, microRNA-130, microRNA-148, microRNA-181, microRNA-194 and microRNA-605 expression in colon cancer tissue
MicroRNA-34, microRNA-130, microRNA-148, microRNA-181, microRNA-194 and microRNA-605 expression in colon cancer tissue
Purpose of the study. Determination of the expression of microRNA‑34, microRNA‑130, microRNA‑148, microRNA‑181, microRNA‑194 and microRNA‑605 in colon tumor tissue depending on the...
Eating Habits Associated with Overweight and Obesity: Case - Control Study in 11-14 year old Adolescents in Hanoi in 2020
Eating Habits Associated with Overweight and Obesity: Case - Control Study in 11-14 year old Adolescents in Hanoi in 2020
Eating habits appears to be an important determinant of dietary intake and may consequently influence overweight and obesity. Understanding the relationship between the nutritional...
Serum exosomal circCCDC66 as a potential diagnostic and prognostic biomarker for pituitary adenomas
Serum exosomal circCCDC66 as a potential diagnostic and prognostic biomarker for pituitary adenomas
PurposeCircular RNAs (circRNAs) play an important role in tumorigenesis, and exosomal circRNAs have the potential to be novel biomarkers for cancer diagnosis. Here, we are committe...
Regulation of miRNA content. Part 1. Editing miRNA. Тailing miRNA
Regulation of miRNA content. Part 1. Editing miRNA. Тailing miRNA
This scientific review presents the processes of regulation of miRNA content. To write the article, information was searched using Scopus, Web of Science, MedLine, PubMed, Google S...
Exosome-Derived Mediators as Potential Biomarkers for Cardiovascular Diseases: A Network Approach
Exosome-Derived Mediators as Potential Biomarkers for Cardiovascular Diseases: A Network Approach
Cardiovascular diseases (CVDs) are widely recognized as the leading cause of mortality worldwide. Despite the advances in clinical management over the past decades, the underlying ...
Exosomal microRNAs as potential biomarkers for osimertinib resistance of non-small cell lung cancer patients
Exosomal microRNAs as potential biomarkers for osimertinib resistance of non-small cell lung cancer patients
BACKGROUND: Osimertinib is an epidermal growth factor receptor-tyrosine kinase inhibitor that specifically targets the T790M mutation in cancer.Unfortunately, most non-small cell l...

